Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 2
1992 4
1993 7
1994 6
1995 4
1996 3
1997 3
1998 3
1999 1
2001 1
2002 2
2004 1
2005 2
2008 1
2013 1
2017 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection.
Collier AC, Coombs RW, Fischl MA, Skolnik PR, Northfelt D, Boutin P, Hooper CJ, Kaplan LD, Volberding PA, Davis LG, Henrard DR, Weller S, Corey L. Collier AC, et al. Ann Intern Med. 1993 Oct 15;119(8):786-93. doi: 10.7326/0003-4819-119-8-199310150-00003. Ann Intern Med. 1993. PMID: 8379600 Clinical Trial.
OBJECTIVE: To assess safety, pharmacokinetics, and in-vivo virologic activity of five different combination regimens of zidovudine and didanosine compared with zidovudine alone in patients with human immunodeficiency virus type 1 (HIV-1) infection. ... …
OBJECTIVE: To assess safety, pharmacokinetics, and in-vivo virologic activity of five different combination regimens of zidovudine an …
Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection.
Lea AP, Faulds D. Lea AP, et al. Drugs. 1996 May;51(5):846-64. doi: 10.2165/00003495-199651050-00009. Drugs. 1996. PMID: 8861550 Review.
Where it has developed, up to a 12-fold increase in resistance has been observed in clinical isolates from patients treated with stavudine for long periods. Stavudine 40mg twice daily and zidovudine 200mg 3 times daily were compared in 822 patients at various stages of …
Where it has developed, up to a 12-fold increase in resistance has been observed in clinical isolates from patients treated with stavudine f …
Controversies in anti-retroviral therapy of adults.
Khoo SH, Wilkins EG. Khoo SH, et al. J Antimicrob Chemother. 1995 Feb;35(2):245-62. doi: 10.1093/jac/35.2.245. J Antimicrob Chemother. 1995. PMID: 7759389 Review.
Only three specific antiretroviral agents are currently licensed for use: zidovudine (ZDV), didanosine (dideoxyinosine, ddI) and zalcitabine (dideoxycytidine, ddC). ...Whenever possible, 'clinical' endpoints (death or clinical progression) are distinguished f …
Only three specific antiretroviral agents are currently licensed for use: zidovudine (ZDV), didanosine (dideoxyinosine, ddI) a …
Targeted therapy of human immunodeficiency virus-related disease.
Mitsuya H, Yarchoan R, Kageyama S, Broder S. Mitsuya H, et al. FASEB J. 1991 Jul;5(10):2369-81. doi: 10.1096/fasebj.5.10.1712326. FASEB J. 1991. PMID: 1712326 Review.
Various nonnucleoside agents have recently been identified to be active against HIV in vitro. HIV-1 protease inhibitors are notable as possible new therapies for HIV-1-related diseases. ...Such therapies will exert major effects against the moribidity and mor …
Various nonnucleoside agents have recently been identified to be active against HIV in vitro. HIV-1 protease inhibitors are no …
Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.
Faulds D, Brogden RN. Faulds D, et al. Drugs. 1992 Jul;44(1):94-116. doi: 10.2165/00003495-199244010-00008. Drugs. 1992. PMID: 1379914 Review.
Didanosine also improved CD4+ cell counts in a phase II/III trial in patients previously treated with zidovudine, whereas cell counts declined in patients continuing zidovudine therapy. However, the effects of didanosine on clinical end-points (disease …
Didanosine also improved CD4+ cell counts in a phase II/III trial in patients previously treated with zidovudine, whereas cell …
A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
McKinney RE Jr, Johnson GM, Stanley K, Yong FH, Keller A, O'Donnell KJ, Brouwers P, Mitchell WG, Yogev R, Wara DW, Wiznia A, Mofenson L, McNamara J, Spector SA. McKinney RE Jr, et al. J Pediatr. 1998 Oct;133(4):500-8. doi: 10.1016/s0022-3476(98)70057-5. J Pediatr. 1998. PMID: 9787687 Clinical Trial.
OBJECTIVE: The Pediatric AIDS Clinical Trials Group (PACTG) Protocol 300 assessed the clinical efficacy and safety of combination zidovudine/lamivudine (ZDV/3TC) compared with either didanosine (ddI) alone or combination ZDV/ddI. ...RESULTS: For the 471 children who …
OBJECTIVE: The Pediatric AIDS Clinical Trials Group (PACTG) Protocol 300 assessed the clinical efficacy and safety of combination zidovud …
The sequential occurrence of pol 215 and pol 41 zidovudine resistance mutations is associated in an additive fashion with low CD4 cell counts and high plasma and cellular HIV viral load.
Si Mohamed A, Kazatchkine M, Piketty C, Cotigny S, Gilquin J, Weiss L, Matta M, Gutmann L, Belec L. Si Mohamed A, et al. Antiviral Res. 1998 Jul;39(1):47-53. doi: 10.1016/s0166-3542(98)00026-6. Antiviral Res. 1998. PMID: 9754949
We report on a cross-sectional study of virological and immunological surrogate markers of HIV infection in 115 patients for whom a determination of the pol 215 and pol 41 zidovudine (ZDV) resistance mutations had been described between January 1995 and Febru …
We report on a cross-sectional study of virological and immunological surrogate markers of HIV infection in 115 patients for w …
Combination therapy for infection due to human immunodeficiency virus type 1.
Caliendo AM, Hirsch MS. Caliendo AM, et al. Clin Infect Dis. 1994 Apr;18(4):516-24. doi: 10.1093/clinids/18.4.516. Clin Infect Dis. 1994. PMID: 7518701 Review.
The preliminary results of the Concorde trial demonstrated the transient clinical benefit of monotherapy with zidovudine (AZT) in asymptomatic persons infected with human immunodeficiency virus type 1 (HIV-1). ...Angela Caliendo review, in this AIDS Commentary, the …
The preliminary results of the Concorde trial demonstrated the transient clinical benefit of monotherapy with zidovudine (AZT) in asy …
Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group.
Japour AJ, Welles S, D'Aquila RT, Johnson VA, Richman DD, Coombs RW, Reichelderfer PS, Kahn JO, Crumpacker CS, Kuritzkes DR. Japour AJ, et al. J Infect Dis. 1995 May;171(5):1172-9. doi: 10.1093/infdis/171.5.1172. J Infect Dis. 1995. PMID: 7538548
Zidovudine resistance mutations at reverse transcriptase codons 215 or 41 were found in two-thirds of human immunodeficiency virus type 1 (HIV-1) isolates obtained at baseline from patients enrolled in an AIDS Clinical Trials Group (ACTG) protocol that compared d …
Zidovudine resistance mutations at reverse transcriptase codons 215 or 41 were found in two-thirds of human immunodeficiency virus ty …
43 results